JP2020512270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512270A5 JP2020512270A5 JP2019515212A JP2019515212A JP2020512270A5 JP 2020512270 A5 JP2020512270 A5 JP 2020512270A5 JP 2019515212 A JP2019515212 A JP 2019515212A JP 2019515212 A JP2019515212 A JP 2019515212A JP 2020512270 A5 JP2020512270 A5 JP 2020512270A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- alkenyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 89
- 125000003118 aryl group Chemical group 0.000 claims description 84
- 125000001072 heteroaryl group Chemical group 0.000 claims description 73
- 239000000539 dimer Substances 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 49
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 30
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000003446 ligand Substances 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000004357 Transferases Human genes 0.000 claims description 10
- 108090000992 Transferases Proteins 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- -1 methoxy, ethoxy Chemical group 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 150000008195 galaktosides Chemical group 0.000 claims description 4
- 150000008134 glucuronides Chemical group 0.000 claims description 4
- 150000002430 hydrocarbons Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 description 26
- 0 CSC(*(*)CN)C(C[C@](C1*)N)C1C=O Chemical compound CSC(*(*)CN)C(C[C@](C1*)N)C1C=O 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023081396A JP2023113699A (ja) | 2017-03-29 | 2023-05-17 | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0039841 | 2017-03-29 | ||
| KR20170039841 | 2017-03-29 | ||
| KR1020180036895A KR101938800B1 (ko) | 2017-03-29 | 2018-03-29 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| KR10-2018-0036895 | 2018-03-29 | ||
| PCT/KR2018/003744 WO2018182341A1 (ko) | 2017-03-29 | 2018-03-29 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081396A Division JP2023113699A (ja) | 2017-03-29 | 2023-05-17 | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512270A JP2020512270A (ja) | 2020-04-23 |
| JP2020512270A5 true JP2020512270A5 (https=) | 2021-05-13 |
| JP7664680B2 JP7664680B2 (ja) | 2025-04-18 |
Family
ID=63876096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515212A Active JP7664680B2 (ja) | 2017-03-29 | 2018-03-29 | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
| JP2023081396A Pending JP2023113699A (ja) | 2017-03-29 | 2023-05-17 | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023081396A Pending JP2023113699A (ja) | 2017-03-29 | 2023-05-17 | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11654197B2 (https=) |
| EP (1) | EP3604311A4 (https=) |
| JP (2) | JP7664680B2 (https=) |
| KR (4) | KR101938800B1 (https=) |
| CN (1) | CN109790171B (https=) |
| AU (1) | AU2018246806B2 (https=) |
| CA (1) | CA3058360A1 (https=) |
| IL (1) | IL269535B2 (https=) |
| MX (1) | MX2019011655A (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016359234B2 (en) | 2015-11-25 | 2022-09-08 | Ligachem Biosciences Inc. | Conjugates comprising peptide groups and methods related thereto |
| KR102847350B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| HRP20240795T1 (hr) | 2015-11-25 | 2024-09-13 | Ligachem Biosciences Inc. | Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima |
| MX2019011655A (es) | 2017-03-29 | 2019-12-19 | Legochem Biosciences Inc | Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este. |
| GB201803342D0 (en) * | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| JP7459063B2 (ja) | 2018-05-09 | 2024-04-01 | レゴケム バイオサイエンシズ， インク． | 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法 |
| WO2020141923A2 (ko) | 2019-01-03 | 2020-07-09 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
| KR20200084802A (ko) | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
| EP3936150A4 (en) | 2019-03-06 | 2023-03-29 | LegoChem Biosciences, Inc. | ANTIBODY-DRUG CONJUGATES COMPRISING ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| WO2021137646A1 (ko) | 2019-12-31 | 2021-07-08 | 주식회사 레고켐바이오사이언스 | 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체 |
| IL307301A (en) | 2021-03-30 | 2023-11-01 | Legochem Biosciences Inc | An antibody-drug conjugate including an antibody against human CLDN18.2 and its use |
| GB202203070D0 (en) * | 2022-03-04 | 2022-04-20 | Iksuda Therapeutics Ltd | Anti-canag antibody conjugate |
| CN115429890B (zh) * | 2022-08-04 | 2024-05-24 | 辽宁键凯科技有限公司 | 一种缀合物及用其制备的抗体药物偶联物 |
| CN115772163B (zh) * | 2022-12-09 | 2025-07-22 | 中国科学院成都生物研究所 | 吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用 |
| EP4389152A1 (en) | 2022-12-23 | 2024-06-26 | Synaffix B.V. | Conjugates of pbd prodrugs |
| JP2026507011A (ja) * | 2023-02-22 | 2026-02-27 | レザルート・サイエンス・インコーポレイテッド | 腫瘍関連マクロファージを標的指向化するための組成物及び方法 |
| CN119798218A (zh) * | 2024-12-31 | 2025-04-11 | 南京优氟医药科技有限公司 | 一种e3酶配体-连接链复合物及其制备方法 |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112739A (en) | 1988-08-02 | 1992-05-12 | Polaroid Corporation | Enzyme controlled release system |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| DE19512484A1 (de) | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
| DK0795334T3 (da) | 1996-03-12 | 2006-06-06 | Sanofi Aventis Deutschland | Nye prodrugs til behandling af tumorer og betændelsessygdomme |
| US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
| JP2001505194A (ja) | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| WO1999057301A1 (en) | 1998-04-30 | 1999-11-11 | Maruha Corporation | Compounds having glucuronic acid derivatives and glucosamine derivatives in the structure, process for producing the same and utilization thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| JP2006510626A (ja) | 2002-12-05 | 2006-03-30 | シエーリング アクチエンゲゼルシャフト | 増殖疾患の処理における部位特異的供給のためのエポチロン類似体 |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| JP2007517035A (ja) | 2003-12-29 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン |
| US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| PE20100251A1 (es) | 2004-09-10 | 2010-04-10 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina |
| WO2006091647A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| CN101287500A (zh) | 2005-08-19 | 2008-10-15 | 恩多塞特公司 | 多药物配体缀合物 |
| TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
| JP2010503706A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | リジン系ポリマーリンカー |
| CN101573384B (zh) | 2006-10-27 | 2013-02-20 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| CN103073641B (zh) | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| WO2009016647A1 (en) * | 2007-08-01 | 2009-02-05 | Council Of Scientific & Industrial Research | Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| ES2527521T3 (es) | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
| ES2667054T3 (es) | 2008-03-24 | 2018-05-09 | Biontech Ag | Nuevas imidazoquinolinas sustituidas |
| GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2010124188A1 (en) | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| US9353140B2 (en) | 2009-11-25 | 2016-05-31 | Academia Sinica | BQC-G, a tumor-selective anti-cancer prodrug |
| KR20110075542A (ko) | 2009-12-28 | 2011-07-06 | 주식회사 효성 | 연료전지 시스템의 워터트랩 장치 |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| FR2960153B1 (fr) | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
| US9591882B2 (en) | 2010-08-05 | 2017-03-14 | Robert LaGrand Duffin | Absorbent sleeve |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| KR20120107741A (ko) | 2011-03-22 | 2012-10-04 | 한국생명공학연구원 | 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법 |
| KR101438265B1 (ko) | 2011-04-04 | 2014-09-05 | 한국생명공학연구원 | Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
| WO2012138102A2 (ko) | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
| WO2012148427A1 (en) | 2011-04-29 | 2012-11-01 | Hewlett-Packard Development Company, L.P. | Systems and methods for in-memory processing of events |
| HUE045348T2 (hu) | 2011-05-08 | 2019-12-30 | Legochem Biosciences Inc | Fehérje-hatóanyag konjugátumok és eljárás elõállításukra |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| JP6228551B2 (ja) | 2012-01-03 | 2017-11-08 | インビクタス オンコロジー プライベート リミテッド | リガンド−標的指向分子およびその方法 |
| CA2871172C (en) | 2012-04-30 | 2020-08-25 | Spirogen Sarl | Pyrrolobenzodiazepines |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CA2905181C (en) * | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| KR20220041957A (ko) | 2013-03-15 | 2022-04-01 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052533A1 (en) * | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| WO2015079376A1 (en) | 2013-11-26 | 2015-06-04 | Novartis Ag | Methods for oxime conjugation to ketone-modified polypeptides |
| JP6701077B2 (ja) | 2013-12-19 | 2020-05-27 | シアトル ジェネティックス， インコーポレイテッド | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| EP2913064A1 (en) | 2014-02-26 | 2015-09-02 | celares GmbH | Branched drug-linker conjugates for the coupling to biological targeting molecules |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| SI3900742T1 (sl) | 2014-09-11 | 2024-10-30 | Seagen Inc. | Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine |
| KR102111983B1 (ko) | 2014-10-24 | 2020-05-18 | 주식회사 소니 인터랙티브 엔터테인먼트 | 제어 장치, 제어 방법, 및 정보 기억 매체 |
| WO2016063595A1 (ja) | 2014-10-24 | 2016-04-28 | ソニー株式会社 | 画像処理装置、画像処理方法及びプログラム |
| BR112017012342A2 (pt) | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| KR20160080832A (ko) | 2014-12-29 | 2016-07-08 | 주식회사 레고켐 바이오사이언스 | 리피바디 유도체-약물 복합체, 그 제조방법 및 용도 |
| EP3244926B8 (en) | 2015-01-14 | 2024-08-21 | The Brigham and Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| HUE055644T2 (hu) | 2015-01-30 | 2022-03-28 | Sutro Biopharma Inc | Hemiasterlin származékok konjugációra és terápiára |
| US11673957B2 (en) | 2015-03-10 | 2023-06-13 | Eureka Therapeutics, Inc. | Anti-ROR2 antibodies |
| EP3842072A1 (en) | 2015-05-18 | 2021-06-30 | Eureka Therapeutics, Inc. | Anti-ror1 antibodies |
| WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
| WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| IL299203A (en) | 2015-10-13 | 2023-02-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Antibody factors specific for human differentiation group 19 and their uses |
| KR102847350B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| AU2016359234B2 (en) | 2015-11-25 | 2022-09-08 | Ligachem Biosciences Inc. | Conjugates comprising peptide groups and methods related thereto |
| HRP20240795T1 (hr) | 2015-11-25 | 2024-09-13 | Ligachem Biosciences Inc. | Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima |
| RU2651776C2 (ru) | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
| SG11201806120WA (en) | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
| MA43821A (fr) | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| WO2017181128A1 (en) | 2016-04-15 | 2017-10-19 | Dynavax Technologies Corporation | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3535299A1 (en) | 2016-11-04 | 2019-09-11 | Novimmune S.A. | Anti-cd19 antibodies and methods of use thereof |
| TWI822055B (zh) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| WO2018119314A1 (en) | 2016-12-22 | 2018-06-28 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| SI3579883T1 (sl) | 2017-02-08 | 2021-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| MX2019011655A (es) | 2017-03-29 | 2019-12-19 | Legochem Biosciences Inc | Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este. |
| WO2018182341A1 (ko) | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| KR20190018400A (ko) | 2017-08-14 | 2019-02-22 | 주식회사 레고켐 바이오사이언스 | EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체 |
| KR102125032B1 (ko) | 2017-09-08 | 2020-06-19 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3725798B1 (en) | 2017-12-15 | 2026-03-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive conjugate, preparation method therefor and use thereof |
| JP7459063B2 (ja) | 2018-05-09 | 2024-04-01 | レゴケム バイオサイエンシズ， インク． | 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法 |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
| ES2929415T3 (es) | 2018-05-25 | 2022-11-29 | Incyte Corp | Compuestos heterocíclicos tricíclicos como activadores de STING |
| WO2019243825A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Small molecule modulators of human sting, conjugates and therapeutic applications |
| CN110903395A (zh) | 2018-09-14 | 2020-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗体、偶联物及其制备方法和用途 |
| WO2020092617A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| KR20200084802A (ko) | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
| EP3936150A4 (en) | 2019-03-06 | 2023-03-29 | LegoChem Biosciences, Inc. | ANTIBODY-DRUG CONJUGATES COMPRISING ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF |
| WO2020249773A1 (en) | 2019-06-12 | 2020-12-17 | Ryvu Therapeutics S.A. | Next-generation modulators of stimulator of interferon genes (sting) |
| LT4004002T (lt) | 2019-07-22 | 2024-10-25 | Lupin Limited | Makrocikliniai junginiai kaip sting agonistai ir jų naudojimo būdai bei metodai |
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| WO2021046426A1 (en) | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
| US11184191B1 (en) | 2019-09-12 | 2021-11-23 | Trend Micro Incorporated | Inspection of network traffic on accelerated platforms |
| WO2022086853A1 (en) | 2020-10-19 | 2022-04-28 | Avidea Technologies, Inc. | Star polymer drug conjugates |
| JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
| TW202246242A (zh) | 2021-01-15 | 2022-12-01 | 美商西健公司 | 免疫調節抗體藥物結合物 |
| WO2022177307A1 (ko) | 2021-02-17 | 2022-08-25 | 한국화학연구원 | 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| IL307301A (en) | 2021-03-30 | 2023-11-01 | Legochem Biosciences Inc | An antibody-drug conjugate including an antibody against human CLDN18.2 and its use |
| AU2022287316A1 (en) | 2021-06-03 | 2023-12-14 | Bristol-Myers Squibb Company | Neodegrader conjugates |
| US20250313557A1 (en) | 2022-04-29 | 2025-10-09 | Ligachem Biosciences Inc. | Imidazo[4,5-c]pyridine derivative compounds as tlr7/8 modulators |
| EP4615853A2 (en) | 2022-11-08 | 2025-09-17 | LigaChem Biosciences Inc. | Heterocyclic compounds as sting agonists |
| JP2026510495A (ja) | 2023-03-10 | 2026-04-07 | リガケム バイオサイエンシズ， インク． | ヒトｌ１ｃａｍに対する抗体を含む抗体－薬物コンジュゲートおよびその使用 |
-
2018
- 2018-03-29 MX MX2019011655A patent/MX2019011655A/es unknown
- 2018-03-29 CN CN201880003365.6A patent/CN109790171B/zh active Active
- 2018-03-29 AU AU2018246806A patent/AU2018246806B2/en active Active
- 2018-03-29 IL IL269535A patent/IL269535B2/en unknown
- 2018-03-29 JP JP2019515212A patent/JP7664680B2/ja active Active
- 2018-03-29 KR KR1020180036895A patent/KR101938800B1/ko active Active
- 2018-03-29 EP EP18774896.7A patent/EP3604311A4/en active Pending
- 2018-03-29 CA CA3058360A patent/CA3058360A1/en active Pending
- 2018-03-29 US US16/328,256 patent/US11654197B2/en active Active
- 2018-08-08 KR KR1020180092623A patent/KR20180110649A/ko not_active Ceased
-
2021
- 2021-05-14 KR KR1020210063019A patent/KR20210058795A/ko not_active Ceased
-
2022
- 2022-01-10 KR KR1020220003168A patent/KR102489250B1/ko active Active
-
2023
- 2023-02-24 US US18/113,948 patent/US12398124B2/en active Active
- 2023-05-17 JP JP2023081396A patent/JP2023113699A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512270A5 (https=) | ||
| TW505636B (en) | Polar-substituted hydrocarbons | |
| JP2014534200A5 (https=) | ||
| JP3749253B2 (ja) | 環状ポリアミン | |
| IL312845B2 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| RU2006139258A (ru) | Бензотриазиновые ингибиторы киназ | |
| JP2019535746A5 (https=) | ||
| SI2300013T1 (en) | Phosphorus derivatives as kinase inhibitors | |
| JP2009515890A5 (https=) | ||
| WO2016065139A1 (en) | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin | |
| WO2014121033A1 (en) | Soluble complexes of drug analogs and albumin | |
| DE602006006199D1 (de) | 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung | |
| JP2021525730A5 (https=) | ||
| US12371417B2 (en) | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | |
| JP2018511628A5 (https=) | ||
| JPWO2021055295A5 (https=) | ||
| WO2015200837A1 (en) | Abiraterone derivatives and non-covalent complexes with albumin | |
| FR2921927A1 (fr) | Imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers | |
| RU2007143507A (ru) | Производные фенилацетилена, обладающие сродством к рецептору mglur 5 | |
| AR045811A1 (es) | 5- arilpirimidinas como agentes ainticancerigenos | |
| CZ286180B6 (cs) | 6,9-bis(Substituované amino)benzo/g/isochinolin-5 10-diony | |
| JPWO2021067242A5 (https=) | ||
| JPWO2021081407A5 (https=) | ||
| EP3400210A2 (fr) | Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer | |
| EA200801536A1 (ru) | Новые тиенопирсульфоновые производные |